Find Bexarotene manufacturers, exporters & distributors on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

11 API Suppliers, 7 USDMF, 3 EU WC, 9 NDC API, 7 Listed Suppliers, $ API Reference Price

11 API Suppliers
7 USDMF
3 EU WC
9 NDC API
7 Listed Suppliers
$ API Reference Price

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

15 FDF Dossiers, 10 FDA Orange Book, 4 Europe, 1 Listed Dossiers

15 FDF Dossiers
10 FDA Orange Book
4 Europe
1 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 75MG, GEL;TOPICAL - 1%

drugProductComposition
CAPSULE;ORAL - 75MG
GEL;TOPICAL - 1%

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 13 SPI Pharma, 7 DKSH, 2 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 2 Actylis, 1 Alcedo Pharmachem, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 15 BASF, 1 Clariant, 10 Corel Pharma Chem, 7 Gangwal Chemicals, 4 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 14 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 5 Microlex e.U, 3 Novo Excipients, 2 Pharmatrans-Sanaq, 3 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 14 Roquette, 8 Seppic, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

46 Coating Systems & Additives, 37 Fillers, Diluents & Binders, 20 Direct Compression, 20 Controlled & Modified Release, 17 Film Formers & Plasticizers, 16 Disintegrants & Superdisintegrants, 14 Chewable & Orodispersible Aids, 14 Parenteral, 14 Taste Masking, 13 Granulation, 13 Solubilizers, 11 Thickeners and Stabilizers, 9 Empty Capsules, 6 Co-Processed Excipients, 5 Coloring Agents, 5 Topical, 4 Vegetarian Capsules, 4 API Stability Enhancers, 3 Surfactant & Foaming Agents, 2 Emulsifying Agents, 2 Rheology Modifiers, 1 Soft Gelatin

DIGITAL CONTENT

11 NEWS #PharmaBuzz

media
11 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 Finished Drug Prices

globalSalesInformation
2 Finished Drug Prices

MARKET PLACE

3 APIs, 1 FDF Dossiers

marketPlace
3 APIs
1 FDF Dossiers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 7,055

MARKET PLACE

API

FDF

1INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

153 RELATED EXCIPIENT COMPANIES

276EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 153559-49-0, Targretin, Targrexin, Lgd1069, Lgd 1069, Lgd-1069

Molecular Formula

C₂₄H₂₈O₂

Molecular Weight

348.5 g/mol

InChI Key

NAVMQTYZDKMPEU-UHFFFAOYSA-N

FDA UNII

A61RXM4375

A rexinoid (an RXR-binding ligand), tetrahydronaphthalene derivative and RETINOID X RECEPTOR antagonist that is used in the treatment of CUTANEOUS T-CELL LYMPHOMA.

Bexarotene is a Retinoid.

1 2D Structure

Bexarotene

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid

2.1.2 InChI

InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)

2.1.3 InChI Key

NAVMQTYZDKMPEU-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C

2.2 Other Identifiers

2.2.1 UNII

A61RXM4375

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-methyl-ttneb

2. 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic Acid

3. Lg69 Compound

4. Lgd 1069

5. Lgd-1069

6. Lgd1069

7. Targretin

2.3.2 Depositor-Supplied Synonyms

1. 153559-49-0

2. Targretin

3. Targrexin

4. Lgd1069

5. Lgd 1069

6. Lgd-1069

7. Lg100069

8. 166175-31-1

9. 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic Acid

10. 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic Acid

11. P-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic Acid

12. Targretyn

13. Lg 100069

14. Lg-100069

15. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic Acid

16. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic Acid

17. Nsc-747528

18. Chembl1023

19. 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic Acid

20. Targret

21. Chebi:50859

22. A61rxm4375

23. 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid

24. Bexarotene [usan]

25. Ncgc00181016-01

26. Ro 26-4455

27. Sr 11247

28. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic Acid

29. Dsstox_cid_20619

30. Dsstox_rid_79514

31. Dsstox_gsid_40619

32. Bexaroteno

33. Bexarotenum

34. Bexaroten

35. Lg 1069

36. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]benzoic Acid

37. Targretin (tn)

38. Cas-153559-49-0

39. Hsdb 7453

40. Sr-05000001480

41. Bexarotene [usan:inn:ban]

42. Unii-a61rxm4375

43. Dtxsid1040619

44. 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic Acid

45. Lg 69

46. Bexarotene- Bio-x

47. 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl)benzoic Acid

48. Mfcd00932428

49. Bexarotene-[13c4]

50. 4k6i

51. Bexarotene [mi]

52. Bexarotene [inn]

53. Bexarotene [jan]

54. Bexarotene [hsdb]

55. Bexarotene Oral(targretin)

56. Bexarotene [vandf]

57. Bexarotene [mart.]

58. Schembl9025

59. Bexarotene [who-dd]

60. Bidd:pxr0021

61. Mls006010146

62. Bexarotene (jan/usan/inn)

63. Bexarotene [ema Epar]

64. Gtpl2807

65. Bexarotene [orange Book]

66. Bexarotene, >=98% (hplc)

67. Hms2089l14

68. Hms3655d19

69. Hms3747c21

70. Hms3884b07

71. 4-[1-(1,1,4,4,7-pentamethyltetralin-6-yl)vinyl]benzoic Acid

72. Act03911

73. Amy24869

74. Bcp04099

75. Zinc1539579

76. Tox21_112666

77. Tox21_302407

78. Bdbm50032675

79. Dl-298

80. Nsc747528

81. Nsc783322

82. S2098

83. Akos015902814

84. Tox21_112666_1

85. Bcp9000396

86. Ccg-221823

87. Cs-0626

88. Db00307

89. Nsc 741061

90. Nsc 747528

91. Nsc-783322

92. Sb17341

93. Ss-4628

94. Benzoic Acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-

95. Ncgc00181016-02

96. Ncgc00181016-03

97. Ncgc00181016-04

98. Ncgc00181016-08

99. Ncgc00181016-20

100. Ncgc00255426-01

101. Ac-24569

102. Bb164246

103. Hy-14171

104. Smr001614557

105. Bcp0726000106

106. Ft-0657110

107. Ft-0702645

108. Sw203810-3

109. D03106

110. Ab01275475-01

111. Ab01275475_02

112. 559b490

113. A809441

114. Q418192

115. J-009026

116. J-519847

117. Sr-05000001480-1

118. Sr-05000001480-2

119. Brd-k92441787-001-02-5

120. 4,6-dichloro-2,3-dihydro-1h-indolehydrochloride

121. 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic Acid

122. 4-[1-(3,5,5,8,8-pentamethyl-2-5,8-dihydronaphthyl)vinyl]benzoic Acid

123. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl]benzoic Acid

124. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-vinyl]benzoic Acid

125. 4-[1-(5,6,7,8,-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic Acid

126. 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-ethenyl]benzoic Acid

127. Benzoic Acid,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₈O₂
Molecular Weight	348.5 g/mol
XLogP3	7.6
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	3
Exact Mass	348.208930132 g/mol
Monoisotopic Mass	348.208930132 g/mol
Topological Polar Surface Area	37.3 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	551
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Targretin
PubMed Health	Bexarotene
Drug Classes	Antineoplastic Agent, Antineoplastic, Dermatological, Dermatological Agent
Drug Label	Targretin (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Each soft gelatin capsule for o...
Active Ingredient	Bexarotene
Dosage Form	Capsule; Gel
Route	Oral; Topical
Strength	1%; 75mg
Market Status	Prescription
Company	Valeant Luxembourg

2 of 2
Drug Name	Targretin
PubMed Health	Bexarotene
Drug Classes	Antineoplastic Agent, Antineoplastic, Dermatological, Dermatological Agent
Drug Label	Targretin (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Each soft gelatin capsule for o...
Active Ingredient	Bexarotene
Dosage Form	Capsule; Gel
Route	Oral; Topical
Strength	1%; 75mg
Market Status	Prescription
Company	Valeant Luxembourg

4.2 Therapeutic Uses

THERAP CAT: Antineoplastic

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 203

Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lyphoma in patients who are refractory to at least one other prior systemic therapy. /Included in US product label/

Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 615

4.3 Drug Warning

May cause fetal harm; teratogenicity and embryolethality demonstrated in animals. No adequate and well-controlled studies to date in humans. Pregnancy should be avoided during therapy. If used during pregnancy, apprise of potential fetal hazard. ... Male patients receiving the drug should use condoms during sexual intercourse with women who are or may become pregnant.

McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 939

Effective contraception must be used for one month prior to the initiation of therapy, during therapy and for at least one month following discontinuation of therapy; it is recommended that two reliable forms of contraception be used simultaneously unless abstinence is the chosen method. Bexarotene can potentially induce metabolic enzymes and thereby theoretically reduce the plasma concentrations of oral or other systemic hormonal contraceptives.

Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 1720

Hyperlipidemia occurred in 79% of patients receiving oral bexarotene in phase II-III clinical studies. Elevations in fasting triglycerides and cholesterol and decreases in HDL-cholesterol were observed in more than half of patients receiving 300 mg/sq m or more. Lipid abnormalities usually developed within 2-4 weeks and were reversible with cessation of therapy. If fasting triglycerides are elevated or become elevated during treatment, antilipemic therapy should be instituted, and the dosage of bexarotene reduced or suspended.

McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 939

Acute pancreatitis has been reported in several patients treated with bexarotene and has been fatal in at least one patient. The manufacturer states that patients with cutaneous T-cell lymphoma (CTCL) who have risk factors for pancreatitis (eg, prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, or drugs associated with pancreatic toxicity or known to increase triglyceride concentrations) generally should not be treated with bexarotene.

McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 939

For more Drug Warnings (Complete) data for BEXAROTENE (15 total), please visit the HSDB record page.

4.4 Drug Indication

Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.

FDA Label

Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR, RXR, RXR). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models.

5.2 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

BEXAROTENE

5.3.2 FDA UNII

A61RXM4375

5.3.3 Pharmacological Classes

Retinoids [CS]; Retinoid [EPC]

5.4 ATC Code

L01XF03

L01XX25

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01X - Other antineoplastic agents

L01XF - Retinoids for cancer treatment

L01XF03 - Bexarotene

5.5 Absorption, Distribution and Excretion

Route of Elimination

Urinary elimination of bexarotene and its known metabolites is a minor excretory pathway (<1% of administered dose).

After oral administration, bexarotene is absorbed with a Tmax of about two hours. ...Studies in patients with advanced malignancies show approximate single dose linearity within the therapeutic range and low accumulation with multiple doses. Plasma bexarotene AUC and Cmax values resulting from a 75 to 300 mg dose were 35% and 48% higher, respectively, after a fat-containing meal than after a glucose solution. Bexarotene is highly bound (>99%) to plasma proteins. The plasma proteins to which bexarotene binds have not been elucidated, and the ability of bexarotene to displace drugs bound to plasma proteins and the ability of drugs to displace bexarotene binding have not been studied.